Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-200 vs HEXABRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Intravascular administration for angiocardiography, aortography, peripheral arteriography, venography, and contrast-enhanced computed tomography (CT),Body cavity imaging: arthrography, hysterosalpingography, and fistulography
Intravascular administration for arteriography, venography, and computed tomography (CT) imaging,Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Off-label: Arthrography, hysterosalpingography, and ductography
Intravenous administration of 1.0-2.0 m L/kg (200 mg iodine/m L) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 m L total. Maximum recommended dose: 2.0 m L/kg.
Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Iopamidol is not metabolized; eliminated unchanged via glomerular filtration.
Not metabolized; eliminated unchanged via glomerular filtration by the kidneys.
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
<2% bound; negligible binding to plasma proteins.
Negligible (<5%); no specific binding proteins
0.24 L/kg; restricted to extracellular fluid, no intracellular penetration.
0.3–0.4 L/kg (confined to extracellular space; does not cross intact blood-brain barrier)
Oral: 0% (not absorbed); IV/IA/Intrathecal: 100% (administered directly into blood/CSF).
Intravenous/Intra-arterial: 100%; Oral: 0% (not absorbed)
e GFR <30 m L/min/1.73m²: Administer with caution, consider prophylaxis with hydration and N-acetylcysteine. e GFR <15: Use only if diagnostic benefit outweighs risk of contrast-induced nephropathy. No specific dose reduction established; consider using lowest feasible volume.
Contraindicated in patients with GFR <30 m L/min/1.73m². For GFR 30-59 m L/min, reduce dose by 50% and ensure adequate hydration.
No specific adjustments recommended for Child-Pugh class A, B, or C. Monitor renal function in patients with severe liver disease due to risk of hepatorenal syndrome.
No specific Child-Pugh based adjustments; use caution in severe hepatic impairment due to risk of hepatorenal syndrome.
Neonates and infants: 1.5-2.0 m L/kg intravenously. Children: 1.0-2.0 m L/kg intravenously; maximum 2.0 m L/kg. For intra-arterial use, consult weight-based dosing guidelines.
Intravenous: 0.5-1 m L/kg (maximum 2 m L/kg) for urography; not recommended for neonates due to risk of acute renal failure.
No specific dose adjustment required based on age alone. Assess renal function (e GFR) in elderly patients as age-related decline is common; follow renal adjustment guidelines. Ensure adequate hydration before and after administration.
Reduce dose by 25-50% in patients >70 years; maintain hydration and monitor renal function.
Not for intrathecal use with ISOVUE-200 (iopamidol injection 41%) due to risk of severe adverse reactions including seizures, paralysis, and death.
Risk of severe, life-threatening adverse reactions including anaphylaxis, cardiovascular collapse, and seizures. Use only when diagnostic information is essential. Resuscitative equipment and trained personnel must be immediately available.
Risk of severe hypersensitivity reactions including anaphylaxis; acute kidney injury in patients with pre-existing renal impairment; CNS adverse effects including seizures with intrathecal administration; thyroid dysfunction in patients with hyperthyroidism; contrast-induced nephropathy.
Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes, or dehydration. Caution in patients with cardiovascular disease, asthma, or known hypersensitivity. Avoid extravasation. Thyroid function tests may be affected. Ensure adequate hydration before and after administration.
Absolute: Hypersensitivity to iopamidol or any component; history of severe adverse reaction to iodinated contrast media; anuria or severe renal impairment (for intravascular use).,Relative: Pregnancy (only if clearly needed); lactation; multiple myeloma; pheochromocytoma; sickle cell disease.
Absolute: Known hypersensitivity to iodinated contrast media, overt thyrotoxicosis, anuria or severe oliguria due to renal disease. Relative: Myeloma, pheochromocytoma, sickle cell disease, pregnancy, and concomitant use of nephrotoxic drugs.
No specific food interactions with ISOVUE-200. Patients are generally encouraged to hydrate with clear fluids before and after the procedure. There are no dietary restrictions. However, in patients with diabetes taking metformin, metformin should be withheld for 48 hours after contrast administration and only resumed after renal function is re-evaluated.
No specific food interactions. Maintain adequate hydration; alcohol should be avoided as it may increase dehydration risk.
Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essential. Second and third trimesters: no known teratogenicity; neonatal thyroid function monitoring recommended after exposure.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of fetal harm from diagnostic doses, though theoretical risks from free iodide exist, especially in the third trimester. The American College of Radiology recommends use only if clearly needed, with minimal dose.
Minimal excretion into breast milk; M/P ratio not established. Iodinated contrast is poorly absorbed orally and poses negligible risk to nursing infant. Interruption of breastfeeding not required.
Iodinated contrast agents are excreted into breast milk in very small amounts (<0.01% of maternal dose). The M/P ratio is not established. Breastfeeding can continue without interruption, but some sources suggest discarding milk for 12-24 hours if desired.
No dose adjustment required in pregnancy; use lowest diagnostic dose. Monitor for volume overload in preeclampsia or compromised cardiac function.
No dose adjustment is recommended for pregnancy. However, use the lowest necessary dose to achieve diagnostic image. Renal function may be altered in pregnancy; ensure adequate hydration to prevent contrast-induced nephropathy.
ISOVUE-200 (iopamidol 41%) is a nonionic, low-osmolality iodinated contrast medium. It is indicated for intrathecal administration in myelography (lumbar, thoracic, cervical, total columnar) and for contrast enhancement in CT and angiocardiography. Key pearls: (1) Monitor renal function before administration due to risk of contrast-induced nephropathy; (2) Prehydrate patients with normal saline to reduce nephrotoxicity; (3) Have emergency equipment available for hypersensitivity reactions; (4) Avoid in patients with known iodine allergy or prior reaction to contrast; (5) Do not mix with other medications in the same syringe; (6) For intrathecal use, ensure proper patient positioning to minimize cephalad flow; (7) Use with caution in patients with sickle cell disease, pheochromocytoma, or hyperthyroidism.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is a low-osmolar, ionic, dimeric contrast medium used for intravascular administration. It has lower osmolality than conventional ionic monomers, reducing the risk of contrast-induced nephropathy and hemodynamic disturbances. Ensure adequate hydration before and after administration. Caution in patients with renal impairment, diabetes, multiple myeloma, or prior contrast reactions. Do not mix with other drugs. Monitor for delayed hypersensitivity reactions.
Inform your doctor if you have ever had an allergic reaction to iodine, contrast dye, or any medications.,Tell your healthcare provider if you have kidney disease, diabetes, asthma, heart disease, or thyroid problems.,You may need to stop taking certain medications (e.g., metformin) before the procedure; follow your doctor's instructions.,You will be asked to drink plenty of fluids before and after the procedure to protect your kidneys.,During injection, you may feel warmth, a metallic taste in the mouth, or nausea; these are usually temporary.,Report any severe symptoms such as difficulty breathing, hives, swelling, or chest pain immediately.,After the procedure, you may resume normal diet unless otherwise instructed.,Breastfeeding women should pump and discard breast milk for 24 hours after contrast administration.
Inform your doctor if you have kidney disease, diabetes, or any allergies, especially to contrast agents.,Drink plenty of fluids before and after the procedure to stay hydrated.,You may experience a warm sensation or metallic taste during injection; this is normal.,Report any symptoms like hives, itching, difficulty breathing, or swelling after the scan.,If you take metformin, you may need to stop it temporarily as directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-200 vs HEXABRIX, answered by our medical review team.
ISOVUE-200 is a Contrast Media that works by Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.. HEXABRIX is a Contrast Media that works by Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-200 and HEXABRIX depend on the specific clinical indication. These are both Contrast Media agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-200 is: Intravenous administration of 1.0-2.0 m L/kg (200 mg iodine/m L) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 m L total. Maximum recommended dose: 2.0 m L/kg.. The standard adult dose of HEXABRIX is: Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-200 and HEXABRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-200 is classified as Category C. Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essen. HEXABRIX is classified as Category C. HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.